Compare Nokia Corp (NOK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs TransMedics Group Inc — how do they compare? Nokia Corp trades at $10.36 (market cap $56.99B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Nokia Corp is far larger — about 20.8× TransMedics Group Inc's market cap, and Nokia Corp pays a 1.61% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and TransMedics Group Inc for 24 Days on average.
| NOK | TMDX | |
|---|---|---|
Market Cap | $56.99B | $2.74B |
Volume | 69,968,204 | 949,331 |
Sector | Technology | Health |
52-Week High | $16.83 | $150.42 |
52-Week Low | $5.25 | $61.99 |
Typical Hold Time | 66 Days | 24 Days |
Enterprise Value | $55.01B | $3.13B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.14, down 4.52% over 24 hours, with a bearish technical signal. The stock shows mixed earnings, beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue has stabilized around $20B annually, with a net income margin of 3.47% in 2025. Analyst consensus is bullish, with a $17.50 price target, supported by recent partnerships in AI and satellite communications.
The outlook is cautiously optimistic, driven by AI infrastructure demand and strategic alliances, but risks include competitive pressures and volatile cash flows. Upside potential exists if execution on growth initiatives improves profitability, while downside risks stem from macroeconomic headwinds and execution missteps.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
